Clinical Trial: Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Determine the Effect of Intradermal AZD3161 on Quantitative Sensory Testing Variables in Normal and UVC Exposed Skin in Healthy V
Brief Summary: The purpose of this study is to investigate the effect of AZD3161 on mechanical pain sensitivity and axon reflex flare in normal and ultraviolet C irradiated skin.
Detailed Summary:
Sponsor: AstraZeneca
Current Primary Outcome: Results of mechanical pain testing using Quantitative Sensory Testing [ Time Frame: Day 1 ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Number of participants with Adverse Events [ Time Frame: Range of 14 days ]
- Vital signs [ Time Frame: Day 1 ](blood pressure, heart rate, pulse)
- Clinical chemistry (urinalysis, hematology) [ Time Frame: At follow up (a range of 8-15 days after Day 1) ]
- The effect of AZD3161 on axon reflex flare in normal and UVC irradiated skin using a Laser doppler scan [ Time Frame: Day 1 ]
Original Secondary Outcome: Same as current
Information By: AstraZeneca
Dates:
Date Received: November 10, 2010
Date Started: December 2010
Date Completion:
Last Updated: April 11, 2011
Last Verified: April 2011